HT-2157 (former development code SNAP-37889) is a drug which acts as a selective non-peptide antagonist for the receptor GAL-3, which is usually activated by the neuropeptide galanin. Blocking this receptor with HT-2157 produced increased serotonin release,[1] as well as producing antidepressant and anxiolytic effects in animal studies,[2] and it was also being researched for treatment of cognitive dysfunction.[3] All human clinical trials were terminated due to safety concerns however, and new GAL-3 antagonists are now being sought instead.[4]
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
ChemSpider |
|
UNII |
|
Chemical and physical data | |
Formula | C21H13F3N2O |
Molar mass | 366.343 g·mol−1 |
3D model (JSmol) |
|
| |
|